The effects of cyclosporine on antioxidant enzyme activities and malondialdehyde levels in rabbit hepatic tissues

Transplant Immunology

Volumn 10, Issue 4, 2002, Pages 255-258

  Durak, Ilker ^a   Kaçmaz, Murat ^a   Burak Cimen M Y ^a   Büyükkoçak, Serap ^a   Elgün, Serenay ^a   Serdar Ozturk H ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Antioxidant enzyme activities; Cyclosporine; Malondialdehyde levels; Rabbit hepatic tissues

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CATALASE; CYCLOSPORIN A; FREE RADICAL; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENZYMATIC ASSAY; ENZYME ACTIVITY; IMMUNITY; LIVER; LIVER TOXICITY; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PEROXIDATION; PRIORITY JOURNAL; RABBIT; SUPERNATANT; VITAMIN SUPPLEMENTATION; ANIMAL; METABOLISM;

ANIMALS; CATALASE; CYCLOSPORINE; GLUTATHIONE PEROXIDASE; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALONDIALDEHYDE; RABBITS; SUPEROXIDE DISMUTASE;

EID: 0036860956     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(02)00076-X     Document Type: Article

References (26)

1. Jazzar A, Fagiuoli S, Caraceni S, et al. Incidence and etiology of hepatic dysfunction in heart transplant recipients receiving a cyclosporine-based triple immunosuppressive therapy. Transplant Proc 1994;26(5):2654.
2. Klompmaker IJ, Gouw AS, Haagsma EB, Verwer R, Slooff MJ. Histological and biochemical effects of cyclosporine A withdrawal from a triple drug regimen after over 2 years of treatment in liver Tx patients. J Hepatol 1995;22(2):151-157.
3. Inselmann G, Lawerenz HU, Nellessen U, Heidemann HT. Enhancement of cyclosporine A induced hepato- and nephrotoxicity by glutathione depletion. Eur J Clin Invest 1994;24(5):355-359.
4. Galan AI, Fernandez E, Moran D, Munoz ME, Jimenez R. Cyclosporine A hepatotoxicity: Effect of prolonged treatment with cyclosporine on biliary lipid secretion in the rat. Clin Exp Pharmacol Physiol 1995;22(4):260-265.
5. Wolf A, Trendelenburg CF, Diez-Fernandez C, Prieto P, Cordier A. Role of glutathione in cyclosporine A in vitro hepatotoxicity. Transplant Proc 1994;26(5):2912-2914.
6. Frenkel K, Gleichauf C. Hydrogen peroxide formation by cells treated with a tumor promoter. Free Radic Res Commun 1991;12-13(Part 2):783-794.
7. Halliwell B, Gutteridge JMC. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984;219(1):1-14.
8. Estabrook RW, Kawano S, Werringloer J. Oxycytochrome P-450: Its breakdown to superoxide for the formation of hydrogen peroxide. Acta Biol Med Ger 1979;38(2-3):423.
9. 2+ homeostasis, cell death, proliferation, and differentiation. Chem Biol Interact 1991;77(1):1-23.
10. Durak I, Güven T, Birey M, et al. Halothane hepatotoxicity and hepatic free radical metabolism in guinea pigs; The effects of vitamin E. Can J Anaesth 1996;43(7):741-748.
11. Van Ye TM, Roza AM, Pieper GM, Henderson J Jr., Johnson CP, Adams MB. Inhibition of intestinal lipid peroxidation does not minimize morphologic damage. J Surg Res 1993;55(5):553-558.
12. Lowry O, Rosenbraugh N, Farr L, Randall R. Protein measurement with folin phenol reagent. J Biol Chem 1951;183:265-275.
13. Durak I, Canbolat O, Kavutcu M, Öztürk HS, Yurtarslani Z. Activities of total, cytoplasmic and mitochondrial superoxide dismutase enzymes in sera and pleural fluids from patients with lung cancer. J Clin Lab Anal 1996;10(1):17-20.
14. Aebi H. Catalase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. New York: Academic Press, 1974. p. 673-677.
15. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70(1):158-169.
16. Kahan BD. Cyclosporine. New Engl J Med 1989;321(25):1725-1738.
17. Pickrell MD, Sawers R, Michael J. Pregnancy after renal transplantation: Severe intrauterine growth retardation during treatment with cyclosporine A. Br Med J 1988;296(6625):825.
18. Kahan BD, Wideman CA, Reid M, et al. The value of serial serum trough cyclosporine levels in human renal transplantation. Transplant Proc 1984;16(5):1195-1199.
19. Maurer G, Lemaire M. Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc 1986;18(6 Suppl 5):25-34.
20. Wonigeit K, Kohlhaw K, Winkler M, Schaefer O, Pichlmayr R. Cyclosporine monitoring in liver allograft recipients: Two distinct patterns of blood level derangement associated with nephrotoxicity. Transplant Proc 1990;22(3):1305-1311.
21. Horina JH, Wirnsberger GH, Kenner L, Holzer H, Krejs GJ. Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. Transplantation 1993;56(5):1091-1094.
22. Davies KJ. Intracellular proteolytic systems may function as secondary antioxidant defences: An hypothesis. J Free Radic Biol Med 1986;2(3):155-173.
23. Kehrer JP. Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol 1993;23(1):21-48.
24. Orrenius S. In: Poli G, Albano E, Dianzani MU, editors. Free Radicals: From Basic Science to Medicine. Basel: Birkhaser Verlag, 1993. p. 47-64.
25. Duruibe VA, Okonmah A, Blyden GT. Effect of cyclosporine on rat liver and kidney glutathione content. Pharmacology 1989;39(4):205-212.
26. Cadenas E, Brigelius R, Akerbook TH. 34th Colloquim-Mosbach, Biological Oxidations. Berlin and Heidelberg: Springer Verlag; 1983.